Trial Profile
A Phase I/II, Single-center, Randomized Double Masked Placebo Controlled Study to Evaluate the Safety and Efficacy of Treatment With AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2020
Price :
$35
*
At a glance
- Drugs AS 101 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Feramda
- 03 Nov 2020 Status changed from discontinued to completed.
- 22 Jul 2020 Status changed from recruiting to discontinued.
- 05 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 May 2020.